Busy week at the Jefferies London Global Healthcare Conference....it concluded with a great panel with Peter Marks from the FDA who highlighted 1) Plans to get rare disease therapies approved more quickly, with bi-partisan support. 2) A willingness to discuss vaccine safety with the public & new government, because "the data is very clear" and a public discussion might iron out some concerns 3) Not too much worry about staff turnover at the agency Met some new (and familiar) investors and a lot of companies! Thanks to Jefferies for another great event 👏
Mark Dainty’s Post
More Relevant Posts
-
Repurposing medicines: the opportunity and the challenges Unlocking game-changing benefits for patients LifeArc https://lnkd.in/dgYbHYDx 1) You need the partnership, insight and the collaboration with patient organisations to ensure rare disease trials are ethically and scientifically appropriate, feasible to conduct and able to demonstrate a meaningful treatment effect Taylor Fields 2) Repurposing Medicines Toolkit - Guidance for navigating the process https://lnkd.in/d6HXF-Aa
To view or add a comment, sign in
-
-
For people with transthyretin amyloidosis (ATTR-CM), early diagnosis is crucial. Delays in diagnosing the condition are very common as the symptoms can be often confused with other conditions. Support #WorldAmyloidosisDay to raise awareness of this rare disease and to show support for those affected by Amyloidosis. https://lnkd.in/exn7C_J3
To view or add a comment, sign in
-
It does not matter if a disease impacts 100 patients or 1 million – every patient is worth fighting for. The increasing attention on the need to find new and better treatment options for those impacted by rare disease is just one of the reasons why I’m hopeful about the future of healthcare. Hear more about the exciting advancements underway in healthcare by watching our latest installment of Pfizer Specialty Voices of Innovation, featuring Hadly Clark, MHSA Clark: https://lnkd.in/gzfyU7gy #VoicesofInnovation #HealthcareInnovation #MilkenInstitute
To view or add a comment, sign in
-
Thank you to everyone who joined us for the Financial Times Digital Dialogue in partnership with Daiichi Sankyo Europe. The webinar brought together a diverse group of Acute Myeloid Leukaemia (AML) patient advocates, caregivers, physicians, and healthcare representatives to discuss vital issues in AML care. Here are the key takeaways from our discussion: - Economic Burden: The significant economic impact of AML on healthcare systems was a major focus. We discussed strategies to mitigate these costs - Patient-Centered Care: The importance of addressing the financial, emotional, and practical burdens on patients, families, and caregivers was emphasised. Enhancing home-based support systems can play a crucial role in this area. - Future Directions: Looking ahead, our panelists called for ongoing research, innovation, and policy reforms to sustain momentum in the fight against AML and ensure better quality of life for all affected. You can watch the discussion on-demand at: https://bit.ly/4bXhGo1
To view or add a comment, sign in
-
💡#RareDisease policy recommendation of the week: "Regulatory bodies and industry organisations should rethink how patient support organisations are funded to better represent their contributions to clinical trial recruitment and registry design. This includes industry and patient support organisations looking towards building a formal arrangement regarding honorarium rates that is consistent and transparent across the sector." This is a recommendation as set out by our recent report 'Delivering effective treatments for rare disease patients'. Read the full report here👉https://lnkd.in/dCWs_BRV
To view or add a comment, sign in
-
-
Just under one month to go until our next webinar 🔔 Join our expert panel as they look at the value of Delphi panels in accelerating patient access to innovative treatments. This webinar aims to provide a comprehensive overview of the Delphi panel methodology, its application in supporting reimbursement decisions and practical considerations for effectively implementing this approach as part of your evidence generation strategy. By attending this webinar, you will: - understand the Delphi panel methodology, including its origins and structured approach for generating expert consensus - discover the value of Delphi Panels in supporting reimbursement decisions - explore practical considerations for implementation in your evidence generation strategy This session is particularly relevant for Market Access teams looking to leverage robust expert opinion and consensus to strengthen their evidence packages and value propositions for reimbursement submissions, particularly for rare disease submissions where clinical data may be limited and expert perspectives are crucial to contextualise evidence for local settings. Click the link to register your free place now: https://lnkd.in/egEWJ999 #webinar #delphipanels #marketaccess #reimbursement
To view or add a comment, sign in
-
-
Join our expert panel Priscila Mazzola, Ben Barron-Millar and Praptee Ghimire as they look at the value of Delphi panels in accelerating patient access to innovative treatments. This webinar aims to provide a comprehensive overview of the Delphi panel methodology, its application in supporting reimbursement decisions and practical considerations for effectively implementing this approach as part of your evidence generation strategy. By attending this webinar, you will: - understand the Delphi panel methodology, including its origins and structured approach for generating expert consensus - discover the value of Delphi Panels in supporting reimbursement decisions - explore practical considerations for implementation in your evidence generation strategy This session is particularly relevant for Market Access teams looking to leverage robust expert opinion and consensus to strengthen their evidence packages and value propositions for reimbursement submissions, particularly for rare disease submissions where clinical data may be limited and expert perspectives are crucial to contextualise evidence for local settings. Click the link to register your free place now: https://lnkd.in/egEWJ999 #webinar #delphipanels #marketaccess #reimbursement
To view or add a comment, sign in
-
-
When launching a rare disease drug, it is essential that your reps are equipped to be trusted experts who can educate and confidently answer questions from healthcare providers, many of whom may have little to no prior knowledge of the disease. Want to ensure your team is fully prepared for a successful rare disease drug launch? Comment below or send us a message to learn how we can help elevate your training and engagement strategies! #RareDisease #PharmaLaunch #SalesTraining #PatientJourney
Your Reps as Trusted Experts: Rare Disease Training that Delivers
https://omnitechmedical.com
To view or add a comment, sign in
-
Looking for comprehensive drug and disease information to support clinical decision-making? Discover the power of DynaMedex®. 💡 From medication safety to disease management, #DynaMedex offers evidence-based resources that can streamline your workflow and support confident decision-making at the point of care. 🔗 Learn more: https://lnkd.in/gJyBiy3T #EvidenceBasedMedicine #ClinicalDecisionSupport #HealthcareInnovation
Drug disease database - DynaMedex with Micromedex
merative.com
To view or add a comment, sign in
-
Sign up for our latest webinar 🔔 Join our expert panel Priscila Mazzola, Ben Barron-Millar and Praptee Ghimire as they look at the value of Delphi panels in accelerating patient access to innovative treatments. This webinar aims to provide a comprehensive overview of the Delphi panel methodology, its application in supporting reimbursement decisions and practical considerations for effectively implementing this approach as part of your evidence generation strategy. By attending this webinar, you will: - understand the Delphi panel methodology, including its origins and structured approach for generating expert consensus - discover the value of Delphi Panels in supporting reimbursement decisions - explore practical considerations for implementation in your evidence generation strategy This session is particularly relevant for Market Access teams looking to leverage robust expert opinion and consensus to strengthen their evidence packages and value propositions for reimbursement submissions, particularly for rare disease submissions where clinical data may be limited and expert perspectives are crucial to contextualise evidence for local settings. Click the link to register your free place now: https://lnkd.in/egEWJ999 #webinar #delphipanels #marketaccess #reimbursement
To view or add a comment, sign in
-
Seeking to Re-Enter Workforce. Strong Healthcare Investing, Finance, Strategy Corporate Access Background Looking to Leverage Vast Network & Problem Solving Skills
3moThe Jefferies conference is becoming the J.P. Morgan Memorial of the UK / EU.